Attached files
| file | filename |
|---|---|
| 8-K - PALOMAR MEDICAL TECHNOLOGIES INC | form8k.htm |
NEWS RELEASE for July 26, 2012 at 8:00AM Eastern Time
| Contacts: | Kerry McAnistan |
| Investor Relations Assistant | |
| Palomar Medical Technologies, Inc. | |
| 781-993-2411 | |
| ir@palomarmedical.com |
PALOMAR MEDICAL REPORTS FINANCIAL RESULTS FOR SECOND QUARTER 2012
BURLINGTON, MA (July 26, 2012)…Palomar Medical Technologies, Inc. (NASDAQ: PMTI), a global leader in laser and other light-based systems for aesthetic treatments, today announced financial results for the second quarter ended June 30, 2012.
Second Quarter 2012 Year-Over-Year Financial Highlights Include:
|
·
|
Total revenues of $19.7 million, up 21%
|
|
·
|
Professional product revenues of $13.0 million, up 30%
|
|
·
|
Professional product revenues gross margin remained consistent at 61%
|
|
·
|
Consumer product revenues of $0.9 million. No consumer revenues were recognized in the second quarter last year.
|
|
·
|
Consumer product revenues gross margin of 14%
|
|
·
|
Loss before taxes of $1.5 million compared to 2011 loss before taxes of $3.9 million
|
|
·
|
Net loss of $1.5 million or $0.08 per share compared to 2011 net loss of $4.0 million or $0.21 per share
|
|
·
|
Cash and investments portfolio of $99 million
|
Chief Executive Officer Joseph P. Caruso commented, “We are very pleased with the continued growth of our professional business as we expand our product portfolio and make key investments in our distribution network. This quarter was the eleventh consecutive quarter of product revenue growth year-over-year. Our professional aesthetic business is close to reaching profitability.”
Mr. Caruso continued, “We continue to upgrade our existing customers with our premium flagship platform, the Palomar Icon™ Aesthetic System, in North America and other strategic parts of the world where we have registration. The Icon system is also opening new doors and expanding our installed base. We are still in the regulatory registration process for many countries and will continue to sell the popular StarLux 500® system until we have registrations in all areas around the world. The Icon platform is the next generation of aesthetic system with melanin detection technology, high peak powers, state of the art cooling, built-in calibration, and an intuitive user interface to provide fast treatments with excellent outcomes and superior user experience.”
Mr. Caruso added, “In June, we expanded our professional product line with the first shipments of the Vectus system. Vectus is a high powered diode laser hair removal system. It is the most powerful diode-based laser system of its kind, with both a large area and a small area tip for full body and small area treatments. The intuitive user interface software and speed make it a natural addition or replacement for any aesthetic hair removal practice. It also comes standard with the Skintel Melanin Optical Density reader that helps the physician deliver the most consistent treatment parameters with the most predictable results. During the quarter, we also began shipping our low price non-ablative fractional laser named the Emerge™ Fractional Laser. We have leveraged many of our consumer products technologies and manufacturing processes to substantially reduce cost and enable us to offer this entry level professional system at a very attractive price. We believe this attractive price point will expand our customer base and allow us to cross sell our full line of professional laser and light-based aesthetic systems. Physician feedback for both has been very positive.”
Mr. Caruso continued, “As we continue to advance our consumer product strategy through the PaloVia® Skin Renewing Laser®, we are gaining valuable knowledge of the market and collecting feedback from the retail channel and our consumers. Although this new category of light-based aesthetic products is not profitable in the short-term, it is providing us with access to a base of consumers that has never been exposed to our professional products or technology.”
- more -
Palomar - Page 2
Professional and consumer segment results for the three months ended June 30, 2012 and 2011 are as follows:
|
For the three months ended June 30,
|
||||||||||||||||||||||||
|
(in thousands)
|
2012
|
2011
|
||||||||||||||||||||||
|
Professional
|
Consumer
|
Total
|
Professional
|
Consumer
|
Total
|
|||||||||||||||||||
|
Revenues
|
$ | 18,770 | $ | 900 | $ | 19,670 | $ | 16,265 | $ | - | $ | 16,265 | ||||||||||||
|
Cost of revenues and royalties
|
7,310 | 776 | 8,086 | 6,334 | 14 | 6,348 | ||||||||||||||||||
|
Gross profit (loss)
|
11,460 | 124 | 11,584 | 9,931 | (14 | ) | 9,917 | |||||||||||||||||
|
Operating expenses
|
11,802 | 1,051 | 12,853 | 13,050 | 928 | 13,978 | ||||||||||||||||||
|
Loss from operations
|
$ | (342 | ) | $ | (927 | ) | $ | (1,269 | ) | $ | (3,119 | ) | $ | (942 | ) | $ | (4,061 | ) | ||||||
Conference Call: As previously announced, Palomar will conduct a conference call and webcast today at 11:30 AM Eastern Time. Management will discuss financial results and strategic matters. If you would like to participate, please call (866) 318-8613 or listen to the webcast in the About Palomar/Investors section of the Company’s website at palomarmedical.com. A webcast replay will also be available.
About Palomar Medical Technologies, Inc.: Palomar designs, produces and sells the most advanced cosmetic lasers and intense pulsed light (IPL) systems to dramatically improve the appearance of women’s and men’s skin. For over 15 years, Palomar has pioneered the science of using lasers and light to improve appearances. As the industry’s technology leader, Palomar has invested in creating cosmetic laser and IPL systems that put real value in the hands of physicians and other professionals to benefit consumers. Thousands of physicians worldwide trust and depend on Palomar technology to not only introduce new aesthetic treatments such as advanced laser hair removal, laser liposuction, skin resurfacing, acne, laser treatments for scars, wrinkle treatment, stretch marks (striae), and photofacials for pigmented and vascular lesions, but to also make them robust, faster, more powerful, and more comfortable for those being treated. In June 2009, Palomar became the first company to receive a 510(k) over-the-counter (“OTC”) clearance from the FDA for a new, patented, home-use, laser device for the treatment of fine lines and wrinkles around the eyes (periorbital wrinkles). This OTC clearance allows the PaloVia® Skin Renewing Laser® to be marketed and sold directly to consumers without a prescription.
For more information on Palomar and its products, visit Palomar’s website at palomarmedical.com for professional products or palovia.com for consumer products. To continue receiving the most up-to-date information and latest news on Palomar as it happens, sign up to receive automatic e-mail alerts by going to the About Palomar/Investors section of the website.
- more -
Palomar - Page 3
With the exception of the historical information contained in this release, the matters described herein contain forward-looking statements, including, but not limited to, statements relating to new markets, future royalty amounts due from third parties, development and introduction of new products, and financial and operating projections. These forward-looking statements are neither promises nor guarantees, but involve risk and uncertainties that may individually or mutually impact the matters herein, and cause actual results, events and performance to differ materially from such forward-looking statements. These risk factors include, but are not limited to, results of future operations, difficulties or delays in developing or introducing new products and keeping them on the market, the results of future research, lack of product demand and market acceptance for current and future products, adverse events, product changes, the effect of economic conditions, challenges in managing joint ventures and research with third parties, the impact of competitive products and pricing, governmental regulations with respect to medical devices, including whether FDA clearance will be obtained for future products and additional applications, the results of litigation, difficulties in collecting royalties, potential infringement of third-party intellectual property rights, factors affecting the Company's future income and resulting ability to utilize its NOLs, and/or other factors, which are detailed from time to time in the Company's SEC reports, including the report on Form 10-K for the year ended December 31, 2011 and the Company's quarterly reports on Form 10-Q. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
- more -
Palomar - Page 4
Palomar Financial Summary:
Consolidated Statements of Operations (Unaudited)
|
Three Months Ended
|
Six Months Ended
|
|||||||||||||||
|
June 30,
|
June 30,
|
|||||||||||||||
|
2012
|
2011
|
2012
|
2011
|
|||||||||||||
|
Revenues:
|
||||||||||||||||
|
Professional product revenues
|
$ | 13,030,019 | $ | 10,053,867 | $ | 24,927,193 | $ | 20,600,515 | ||||||||
|
Consumer product revenues
|
900,409 | - | 1,879,177 | - | ||||||||||||
|
Service revenues
|
3,545,564 | 3,907,312 | 7,315,807 | 7,742,499 | ||||||||||||
|
Royalty revenues
|
1,527,203 | 1,748,510 | 3,325,265 | 4,966,849 | ||||||||||||
|
Other revenues
|
666,664 | 555,556 | 1,222,220 | 1,111,112 | ||||||||||||
|
Total revenues
|
19,669,859 | 16,265,245 | 38,669,662 | 34,420,975 | ||||||||||||
|
Costs and expenses:
|
||||||||||||||||
|
Cost of professional product revenues
|
5,045,188 | 3,970,251 | 9,946,286 | 8,273,817 | ||||||||||||
|
Cost of consumer product revenues
|
776,364 | 14,444 | 1,610,747 | 55,980 | ||||||||||||
|
Cost of service revenues
|
1,654,401 | 1,663,738 | 3,314,364 | 3,455,905 | ||||||||||||
|
Cost of royalty revenues
|
610,881 | 699,404 | 1,330,106 | 1,986,739 | ||||||||||||
|
Research and development
|
2,836,041 | 3,880,308 | 6,208,302 | 7,528,224 | ||||||||||||
|
Selling and marketing
|
7,074,465 | 6,315,511 | 13,755,990 | 11,891,282 | ||||||||||||
|
General and administrative
|
2,941,484 | 3,782,204 | 6,093,444 | 7,267,605 | ||||||||||||
|
Total costs and expenses
|
20,938,824 | 20,325,860 | 42,259,239 | 40,459,552 | ||||||||||||
|
Loss from operations
|
(1,268,965 | ) | (4,060,615 | ) | (3,589,577 | ) | (6,038,577 | ) | ||||||||
|
Interest income
|
85,989 | 88,691 | 174,992 | 202,072 | ||||||||||||
|
Other (loss) income
|
(270,528 | ) | 29,476 | (258,726 | ) | 39,318 | ||||||||||
|
Loss before income taxes
|
(1,453,504 | ) | (3,942,448 | ) | (3,673,311 | ) | (5,797,187 | ) | ||||||||
|
Provision for income taxes
|
18,143 | 56,473 | 90,121 | 95,726 | ||||||||||||
|
Net loss
|
$ | (1,471,647 | ) | $ | (3,998,921 | ) | $ | (3,763,432 | ) | $ | (5,892,913 | ) | ||||
|
Net loss per share:
|
||||||||||||||||
|
Basic
|
$ | (0.08 | ) | $ | (0.21 | ) | $ | (0.20 | ) | $ | (0.32 | ) | ||||
|
Diluted
|
$ | (0.08 | ) | $ | (0.21 | ) | $ | (0.20 | ) | $ | (0.32 | ) | ||||
|
Weighted average shares outstanding:
|
||||||||||||||||
|
Basic
|
18,821,644 | 18,699,608 | 18,835,623 | 18,688,202 | ||||||||||||
|
Diluted
|
18,821,644 | 18,699,608 | 18,835,623 | 18,688,202 | ||||||||||||
- more -
Palomar - Page 5
Consolidated Balance Sheets (Unaudited)
|
|
||||||||
|
June 30,
|
December 31,
|
|||||||
|
2012
|
2011
|
|||||||
|
Assets
|
||||||||
|
Current assets:
|
||||||||
|
Cash, cash equivalents and short-term investments
|
$ | 86,192,174 | $ | 87,817,176 | ||||
|
Accounts receivable, net
|
10,478,984 | 9,853,682 | ||||||
|
Inventories
|
25,241,532 | 21,175,754 | ||||||
|
Other current assets
|
1,096,392 | 999,919 | ||||||
|
Total current assets
|
123,009,082 | 119,846,531 | ||||||
|
Marketable securities and other investments
|
12,484,167 | 21,268,777 | ||||||
|
Property and equipment, net
|
36,458,792 | 36,713,578 | ||||||
|
Other assets
|
440,135 | 232,594 | ||||||
|
Total assets
|
$ | 172,392,176 | $ | 178,061,480 | ||||
|
Liabilities and Stockholders' Equity
|
||||||||
|
Current Liabilities:
|
||||||||
|
Accounts payable
|
$ | 2,831,664 | $ | 3,476,030 | ||||
|
Accrued liabilities
|
9,951,349 | 12,437,921 | ||||||
|
Deferred revenue
|
4,010,724 | 4,423,980 | ||||||
|
Total current liabilities
|
16,793,737 | 20,337,931 | ||||||
|
Accrued income taxes
|
3,129,577 | 3,082,356 | ||||||
|
Total liabilities
|
$ | 19,923,314 | $ | 23,420,287 | ||||
|
Stockholders’ equity:
|
||||||||
|
Preferred stock, $.01 par value-
|
||||||||
|
Authorized - 1,500,000 shares
|
||||||||
|
Issued - none
|
- | - | ||||||
|
Common stock, $.01 par value-
|
||||||||
|
Authorized - 45,000,000 shares
|
||||||||
|
Issued and Outstanding - 19,590,244 and 19,542,677 and 19,573,244 and 19,573,244 shares, respectively
|
195,903 | 195,733 | ||||||
|
Additional paid-in capital
|
220,482,245 | 219,062,043 | ||||||
|
Accumulated other comprehensive loss
|
(93,120 | ) | (263,849 | ) | ||||
|
Accumulated deficit
|
(68,116,166 | ) | (64,352,734 | ) | ||||
|
Treasury stock, at cost – 47,567 and 0 shares, respectively
|
- | - | ||||||
|
Total stockholders’ equity
|
$ | 152,468,862 | $ | 154,641,193 | ||||
|
Total liabilities and stockholders’ equity
|
$ | 172,392,176 | $ | 178,061,480 | ||||
# # #